Replies to post #131274 on Biotech Values

[genisi]

But the program also has a third phase III trial - FISSION that will test 12 weeks of PSI-7977/RBV vs. 24 weeks of PEG-IFN/RBV in 500 treatment-naïve GT 2/3 patients. So not restricted to patients that can not tolerate INF.